International Immunology, Vol. 12, No. 4, 555-562,
April 2000
© 2000 Japanese Society for Immunology
A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity
Biomedical Research Laboratories,
1 Neuroscience and Immunology Research Laboratories, and
2 Medical Safety Research Laboratories, Sankyo Co., Ltd, Tokyo 140-8710, Japan
3 Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki 216-8512, Japan
4 Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan
Correspondence to: N. Serizawa
Defects in Fas-mediated apoptosis are implicated in autoimmune diseases including rheumatoid arthritis (RA). Although induction of Fas-mediated apoptosis could have therapeutic effects on these diseases, it might cause deleterious effects in liver as Fas ligand or an agonistic anti-murine Fas antibody Jo2 causes severe hepatic injury in mice. We report here on the interesting characteristics of the newly obtained anti-Fas mAb, HFE7A, which cross-reacts with the Fas molecules of various species ranging from human to mouse and mitigates autoimmune symptoms without hepatotoxicity in mice. The administration of HFE7A to mice induced apoptosis in the thymocytes, although administration of HFE7A to mice or to marmosets did not induce any sign of hepatitis. The effect of HFE7A on liver is different from that of anti-murine Fas antibody Jo2, which causes acute and lethal hepatic injury to mice. Administration of HFE7A reduced lymphadenopathy and abnormal T cells in MRL-gld/gld mice. HFE7A induced apoptosis in synovial cells prepared from RA patients. Surprisingly, HFE7A protected mice from fulminant hepatitis induced by Jo2. Therefore, HFE7A is a potential therapeutic antibody not only for autoimmune diseases including RA but also for fulminant hepatitis.
Keywords: anti-Fas mAb, apoptosis, dual function, hepatotoxicity, lymphadenopathy, rheumatoid arthritis
Transmitting editor: S. Nagata
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Herrmann, L. Grosse-Hovest, T. Otz, P. H. Krammer, H.-G. Rammensee, and G. Jung Construction of Optimized Bispecific Antibodies for Selective Activation of the Death Receptor CD95 Cancer Res., February 15, 2008; 68(4): 1221 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bagnoli, E. Balladore, E. Luison, P. Alberti, F. Raspagliesi, B. Marcomini, S. Canevari, and D. Mezzanzanica Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment Mol. Cancer Ther., February 1, 2007; 6(2): 762 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Okamoto, J.-i. Fujisawa, M. Reth, and S. Yonehara Human T-cell leukemia virus type-I oncoprotein Tax inhibits Fas-mediated apoptosis by inducing cellular FLIP through activation of NF-{kappa}B Genes Cells, February 1, 2006; 11(2): 177 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nakayama, Y. Ogawa, Y. Yoshigae, Y. Onozawa, A. Yonemura, M. Saito, K. Ichikawa, T. Yamoto, T. Komai, T. Tatsuta, et al. A humanized anti-human Fas antibody, R-125224, induces apoptosis in type I activated lymphocytes but not in type II cells Int. Immunol., January 1, 2006; 18(1): 113 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. McDermott, D. B. Longley, L. Galligan, W. Allen, T. Wilson, and P. G. Johnston Effect of p53 Status and STAT1 on Chemotherapy-Induced, Fas-Mediated Apoptosis in Colorectal Cancer Cancer Res., October 1, 2005; 65(19): 8951 - 8960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sakamaki, C. Takagi, K. Kominami, S.-i. Sakata, Y. Yaoita, H. Y. Kubota, M. Nozaki, S. Yonehara, and N. Ueno The adaptor molecule FADD from Xenopus laevis demonstrates evolutionary conservation of its pro-apoptotic activity Genes Cells, December 1, 2004; 9(12): 1249 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kotone-Miyahara, K. Yamashita, K.-K. Lee, S. Yonehara, T. Uchiyama, M. Sasada, and A. Takahashi Short-term delay of Fas-stimulated apoptosis by GM-CSF as a result of temporary suppression of FADD recruitment in neutrophils: evidence implicating phosphatidylinositol 3-kinase and MEK1-ERK1/2 pathways downstream of classical protein kinase C J. Leukoc. Biol., November 1, 2004; 76(5): 1047 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Longley, W. L. Allen, U. McDermott, T. R. Wilson, T. Latif, J. Boyer, M. Lynch, and P. G. Johnston The Roles of Thymidylate Synthase and p53 in Regulating Fas-Mediated Apoptosis in Response to Antimetabolites Clin. Cancer Res., May 15, 2004; 10(10): 3562 - 3571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. V. Proussakova, N. A. Rabaya, A. B. Moshnikova, E. S. Telegina, A. Turanov, M. G. Nanazashvili, and I. P. Beletsky Oligomerization of Soluble Fas Antigen Induces Its Cytotoxicity J. Biol. Chem., September 19, 2003; 278(38): 36236 - 36241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Greil, G. Anether, K. Johrer, and I. Tinhofer Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools J. Leukoc. Biol., September 1, 2003; 74(3): 311 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xu, A. J. Szalai, T. Zhou, K. R. Zinn, T. R. Chaudhuri, X. Li, W. J. Koopman, and R. P. Kimberly Fc{gamma}Rs Modulate Cytotoxicity of Anti-Fas Antibodies: Implications for Agonistic Antibody-Based Therapeutics J. Immunol., July 15, 2003; 171(2): 562 - 568. [Abstract] [Full Text] [PDF]
|
|